These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 92421)

  • 1. Pepstatin, an inhibitor of acid kininogenases and ascites retardant in neoplastic disease.
    Greenbaum LM
    Fed Proc; 1979 Dec; 38(13):2788-91. PubMed ID: 92421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pepstatin, an inhibitor of leukokinin formation and ascitic fluid accumulation.
    Greenbaum LM; Grebow P; Johnston M; Prakash A; Semente G
    Cancer Res; 1975 Mar; 35(3):706-10. PubMed ID: 46779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pepstatin inhibition of cathepsin D in situ and its modification of leukokinin formation: HPLC separation of fluorescamine-treated kinins.
    Greenbaum LM; Sutherland JH; Narayan TK
    Adv Exp Med Biol; 1983; 156 (Pt B)():783-7. PubMed ID: 6190383
    [No Abstract]   [Full Text] [Related]  

  • 4. Regional brain distribution of cathepsin D activity: its inhibition in vivo following central infusion of pepstatin in the rat.
    Buccafusco JJ; Goldstein BD; Greenbaum LM
    Res Commun Chem Pathol Pharmacol; 1982 Apr; 36(1):157-60. PubMed ID: 7079582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Host cathepsin D response to tumor in the normal and pepstatin-treated mouse.
    Greenbaum LM; Sutherland JH
    Cancer Res; 1983 Jun; 43(6):2584-7. PubMed ID: 6850578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further studies of the effect of pepstatin on ascites accumulation in tumor-bearing mice.
    Greenbaum LM; Esumi H; Sato S
    Cancer Lett; 1979 Jul; 7(2-3):91-6. PubMed ID: 476614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The isolation of leukokinin-H and leukokininogen from human ascites fluid; their properties and role.
    Greenbaum LM; Semente G; Grebow P; Roffman S
    Adv Exp Med Biol; 1979; 120B():205-14. PubMed ID: 92880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolongation of serum half-life of interleukin 2 and augmentation of lymphokine-activated killer cell activity by pepstatin in mice.
    Ohnishi H; Lin KM; Chu TM
    Cancer Res; 1990 Feb; 50(4):1107-12. PubMed ID: 2297759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimetastatic activity of adriamycin in combinations with proteinase inhibitors in mice.
    Leto G; Tumminello FM; Gebbia N; Woynarowska B; Bernacki RJ
    Anticancer Res; 1990; 10(1):265-9. PubMed ID: 2334138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pepstatin, an ascites retardant of L1210 tumor-bearing mice.
    Greenbaum LM; Semente G
    J Natl Cancer Inst; 1977 Jul; 59(1):259-62. PubMed ID: 875057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological activity of aspartic proteinase inhibitors related to pepstatin.
    Gunn JM; Owens RA; Liu WS; Glover GI
    Acta Biol Med Ger; 1981; 40(10-11):1547-53. PubMed ID: 6805191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of lactoyl-pepstatin and the pepsin inhibitor peptide on pig cathepsin D.
    Kay J; Afting EG; Aoyagi T; Dunn BM
    Biochem J; 1982 Jun; 203(3):795-7. PubMed ID: 7115318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cysteine proteinase activity by Z-Phe-Phe-diazomethane and of aspartic proteinase activity by pepstatin in different organs from some animals and isolated cells from rat liver.
    Riemann S; Kirschke H; Wiederanders B; Brouwer A; Shaw E; Bohley P
    Acta Biol Med Ger; 1982; 41(1):83-8. PubMed ID: 7051705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of human cathepsin D with the inhibitor pepstatin.
    Knight CG; Barrett AJ
    Biochem J; 1976 Apr; 155(1):117-25. PubMed ID: 938470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pepstatin A, an aspartic proteinase inhibitor, suppresses RANKL-induced osteoclast differentiation.
    Yoshida H; Okamoto K; Iwamoto T; Sakai E; Kanaoka K; Hu JP; Shibata M; Hotokezaka H; Nishishita K; Mizuno A; Kato Y
    J Biochem; 2006 Mar; 139(3):583-90. PubMed ID: 16567424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscle aspartyl protease (cathepsin D) activity: detection using a chromophoric substrate and relation to wasting in DBA/2 mice implanted with leukemic L1210 tumor cells.
    Bolger GT; Jaramillo J
    Can J Physiol Pharmacol; 1996 Oct; 74(10):1141-8. PubMed ID: 9022834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of mouse muscular dystrophy with the protease inhibitor pepstatin.
    Schorr EE; Arnason BG; Aström KE; Darzynkiewicz Z
    J Neuropathol Exp Neurol; 1978 May; 37(3):263-8. PubMed ID: 660216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Isolation of cathepsin D from the aorta using pepstatin sepharose].
    Pichugin AL; Kazakova OV
    Vopr Med Khim; 1979; 25(6):741-3. PubMed ID: 516535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pepstatin A-sensitive aspartic proteases in lysosome are involved in degradation of the invariant chain and antigen-processing in antigen presenting cells of mice infected with Leishmania major.
    Zhang T; Maekawa Y; Yasutomo K; Ishikawa H; Fawzy Nashed B; Dainichi T; Hisaeda H; Sakai T; Kasai M; Mizuochi T; Asao T; Katunuma N; Himeno K
    Biochem Biophys Res Commun; 2000 Sep; 276(2):693-701. PubMed ID: 11027533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No role for pepstatin-A-sensitive acidic proteinases in reovirus infections of L or MDCK cells.
    Kothandaraman S; Hebert MC; Raines RT; Nibert ML
    Virology; 1998 Nov; 251(2):264-72. PubMed ID: 9837790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.